Omnicell, Inc. (NASDAQ: OMCL), which provides automation and business analytics solutions for medication and supply management, paid $275 million for Aesynt, a portfolio company of Francisco Partners. Aesynt, which Francisco only acquired in 2013, brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics. Aesynt’s robust medication management tools will complement Omnicell’s product portfolio and international footprint.
Pharma Automation Company Gets $275 Million
by Lisa Phillips | Nov 2, 2015 8:59 am | Other Services, Private Equity
Categories
- Ambulatory Surgery Centers
- Behavioral Health Care
- Biotechnology
- CDMO
- CRO
- eHealth
- Healthcare M&A News Leads
- Healthcare Market Updates
- Healthcare Staffing
- Home Health & Hospice
- Hospitals
- Laboratories, MRI & Dialysis
- Long-Term Care
- Managed Care
- Medical Devices
- Medical Office Buildings
- Occupational Health
- Other Services
- Pharmaceuticals
- Physician Medical Groups
- Private Equity
- Rehabilitation
- SPAC
- Specialty Pharmacies
- Uncategorized
- Urgent Care Centers